Equities research analysts at Brean Capital raised their price target on shares of Inovio Pharmaceuticals (NYSE:INO) from $3.00 to $4.00 in a research note issued to investors on Friday, ARN reports. The firm currently has a “buy” rating on the stock. Brean Capital’s target price would suggest a potential upside of 58.10% from the company’s current price.
Separately, analysts at Aegis reiterated a “hold” rating on shares of Inovio Pharmaceuticals in a research note to investors on Wednesday, November 13th. They now have a $2.50 price target on the stock.
Inovio Pharmaceuticals (NYSE:INO) opened at 2.53 on Friday. Inovio Pharmaceuticals has a 52 week low of $0.49 and a 52 week high of $3.03. The stock has a 50-day moving average of $2.38 and a 200-day moving average of $2.01. The company’s market cap is $527.2 million.
Inovio Pharmaceuticals (NYSE:INO) last announced its earnings results on Monday, November 11th. The company reported ($0.16) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.02) by $0.14. The company had revenue of $9.50 million for the quarter, compared to the consensus estimate of $2.99 million. On average, analysts predict that Inovio Pharmaceuticals will post $-0.31 earnings per share for the current fiscal year.
Inovio Pharmaceuticals, Inc, formerly Inovio Biomedical Corporation, is engaged in the discovery, development, and delivery of vaccines, called deoxyribonucleic acid (NYSE:INO) vaccines, focused on cancers and infectious diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.